Study #2014-0431
Allogeneic Transplantation Using Venetoclax, Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients with AML and MDS
MD Anderson Study Status
Enrolling
Treatment Agent
Busulfan, Cladribine, Fludarabine Phosphate, Venetoclax
Description
This randomized phase II trial studies how well venetoclax and sequential busulfan, cladribine, and fludarabine phosphate before donor stem cell transplant work in treating patients with acute myelogenous leukemia or myelodysplastic syndrome. Giving chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndrome
Study phase:
II
Physician name:
Uday Popat
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-877-632-6789